ASH 2020 | UCART22 for R/R B-cell ALL
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, presents the preliminary results of Balli-01 (NCT04150497), a Phase I study trialling the chimeric antigen receptor (CAR) T-cell therapy, UCART22, in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL). UCART22 is a T-cell product manufactured from non-HLA matched healthy donor cells and engineered to express an anti-CD22 chimeric antigen receptor. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Nitin Jain, MD, has received research funding from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Aprea Therapeutics and Fate Therapeutics; and has participated in advisory boards or received honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Adaptive Biotechnologies, Servier, Precision Biosciences, Beigene, TG Therapeutics and ADC Therapeutics.
